Join to View Full Profile
125 Red Creek DrRochester, NY 14623
Phone+1 585-486-0600
Fax+1 585-486-0649
Dr. Falkson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Carla Falkson, based in Rochester, NY, is a specialist in oncology with a subspecialty in breast cancer. She completed her fellowship in hematology and medical oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Dr. Falkson has expertise in immunotherapy, personalized medicine, neoplasm staging, and various treatments for breast cancer including clinical trials. Her publications include significant studies on breast cancer treatment strategies. Additionally, she has been involved in numerous clinical trials addressing various cancers. Dr. Falkson has been recognized with honors such as the Unsung Hero Award from the Division of Hematology Oncology at UAB, Regional Top Doctor by Castle Connolly, and the Meaningful Use Stage 1 Certification.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
University of Pretoria Faculty of MedicineClass of 1982
Certifications & Licensure
NY State Medical License 2019 - 2027
AL State Medical License 2000 - 2019
Awards, Honors, & Recognition
- Unsung Hero Award Division of hematology Oncology Dept Medicine UAB, 2018
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Start of enrollment: 2005 Jul 01
- Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. Start of enrollment: 2005 Oct 01
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsOptimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of D...Dario Trapani, Qingchun Jin, Kathy D Miller, Hope S Rugo, Katherine E Reeder-Hayes
Clinical Breast Cancer. 2025-06-01 - A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELE...Amy S Clark, Fengmin Zhao, Paula Klein, Alberto J Montero, Carla Falkson
Clinical Cancer Research. 2025-04-29 - 13 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
- Breast Cancer and the COVID Vaccine: What You Need to KnowMarch 1st, 2021
Guided by Research, Wilmot’s Breast Cancer Program Comes of AgeOctober 19th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
